No surprise here...China's wealthiest individual has a biotech/vaccine manufacturer.
"Outside of his stake in Nongfu Spring, he is the head of a vaccine maker, Beijing Wantai Biological Pharmacy. That company went public in Shanghai this year, which also helped boost Zhong's wealth."
Zhong Shanshan, the founder of the popular Chinese bottled water brand Nongfu Spring, has overtaken Alibaba ( BABA) founder Jack Ma to become the country's wealthiest person, according to the Bloomberg Billionaires index.
cnn.com
Earlier this year, China was already home to most of the world's billionaires, with more than the United States and India combined, according to a global rich list compiled by the Hurun Report.
According to Bloomberg calculations, Zhong's estimated net worth was $20 billion last month — suggesting he has tripled his fortune in just a matter of weeks.
The boom is expected to continue.
In recent months, a parade of initial public offerings has unfolded around the world, especially in China.
Hong Kong is the world's second most popular venue for stock market listings so far this year, behind only the tech-heavy Nasdaq in New York, according to data provider Refinitiv.
Delemir Delev fda.gov
International Business Development Director Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
No. 31 Kexueyuan Road Changping District, Beijing, CN 102206
Device: WANTAI SARS-CoV-2 Ab ELISA
Company: Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
Indication: Qualitative detection of total antibodies (including IgG and IgM) to SARS-CoV-2 in human serum and Acid Citrate Dextrose (ACD) plasma. Intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection.
Emergency use of this test is limited to authorized laboratories. Authorized Laboratories: Laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. 263a, that meet requirements to perform high complexity tests.
Dear Mr. Delev:
This letter is in response to your1 request that the Food and Drug Administration (FDA) issue an Emergency Use Authorization (EUA) for emergency use of your product, 2
pursuant to Section 564 of the Federal Food, Drug, and Cosmetic Act (the Act) (21 U.S.C. §360bbb-3).
On February 4, 2020, pursuant to Section 564(b)(1)(C) of the Act, the Secretary of the Department of Health and Human Services (HHS) determined that there is a public health emergency that has a significant potential to affect national security or the health and security of United States citizens living abroad, and that involves the virus that causes COVID-19.
Pursuant to Section 564 of the Act, and on the basis of such determination, the Secretary of HHS then declared that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of the virus that causes COVID-19 subject to the terms of any authorization issued under Section 564(a) of the Act. 3 1 For ease of reference, this letter will use the term “you” and related terms to refer to Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. 2 For ease of reference, this letter will use the term “your product” to refer to the WANTAI SARS-CoV-2 Ab ELISA for the indication identified above. 3 U.S. Department of Health and Human Services, Determination of a Public Health Emergency and Declaration that Circumstances Exist Justifying Authorizations Pursuant to Section 564(b) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3. 85 FR 7316 (February 7, 2020). |
